Phase 2
-
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
Phase 2 · randomised · 50 people · 1 site in China · Recruiting now
-
NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC
Phase 2 · randomised · 100 people · 1 site in China · Recruiting now
-
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
Phase 2 · randomised · 100 people · 30 sites in 6 countries · Recruiting now
-
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Phase 2 · randomised · 208 people · 2 sites in 2 countries · Recruiting now
-
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Phase 2 · 90 people · 9 sites in 3 countries · Recruiting now
-
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Phase 2 · randomised · 100 people · 2 sites in United States · Recruiting now